Tanyi, Janos L.Chiang, Cheryl L. -L.Chiffelle, JohannaThierry, Anne-ChristineBaumgartener, PetraHuber, FlorianGoepfert, ChristineTarussio, DavidTissot, StephanieTorigian, Drew A.Nisenbaum, Harvey L.Stevenson, Brian J.Guiren, Hajer FritahAhmed, RitaparnaHuguenin-Bergenat, Anne-LaureZsiros, EmeseBassani-Sternberg, MichalMick, RosemariePowell, Daniel J., Jr.Coukos, GeorgeHarari, AlexandreKandalaft, Lana E.2021-04-102021-04-102021-04-102021-03-1510.1038/s41541-021-00297-5https://infoscience.epfl.ch/handle/20.500.14299/177192WOS:000629169400001T cells are important for controlling ovarian cancer (OC). We previously demonstrated that combinatorial use of a personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide (Cy) elicited neoantigen-specific T cells and prolonged OC survival. Here, we hypothesize that adding acetylsalicylic acid (ASA) and low-dose interleukin (IL)-2 would increase the vaccine efficacy in a recurrent advanced OC phase I trial (NCT01132014). By adding ASA and low-dose IL-2 to the OCDC-Bev-Cy combinatorial regimen, we elicited vaccine-specific T-cell responses that positively correlated with patients' prolonged time-to-progression and overall survival. In the ID8 ovarian model, animals receiving the same regimen showed prolonged survival, increased tumor-infiltrating perforin-producing T cells, increased neoantigen-specific CD8(+) T cells, and reduced endothelial Fas ligand expression and tumor-infiltrating T-regulatory cells. This combinatorial strategy was efficacious and also highlighted the predictive value of the ID8 model for future ovarian trial development.ImmunologyMedicine, Research & ExperimentalResearch & Experimental Medicinetext::journal::journal article::research article